Chemotherapy At Home Services Market Report 2026

The chemotherapy at home services market size has grown rapidly in recent years. It will grow from $1.94 billion in 2025 to $2.16 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to expansion of outpatient cancer treatment programs, rising demand for patient-centric care, availability of portable infusion pumps, increasing healthcare cost pressures, improved oncology drug formulations.

The chemotherapy at home services market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing investments in home healthcare services, growing adoption of digital oncology monitoring tools, expansion of targeted cancer therapies, rising preference for decentralized care delivery, improved reimbursement support for home chemotherapy. Major trends in the forecast period include increasing adoption of home-based oncology care models, rising use of portable infusion technologies, growing integration of remote patient monitoring, expansion of personalized chemotherapy regimens, enhanced focus on patient comfort and safety.

The growing prevalence of cancer is anticipated to drive the expansion of the chemotherapy-at-home services market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells within the body. The rising incidence of cancer is attributed to factors such as aging populations, lifestyle changes, environmental exposures, genetic susceptibility, and improved detection through advanced diagnostic technologies. Chemotherapy-at-home services enable patients to receive cancer treatment in the comfort of their own homes, enhancing convenience, improving quality of life, and reducing the need for frequent hospital visits. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, approximately 1,958,310 new cancer cases were reported in the United States, with an estimated 609,820 cancer-related deaths projected to occur in 2023. Therefore, the increasing burden of cancer is fueling the growth of chemotherapy-at-home services.

The rise in healthcare expenditure is also expected to propel the growth of the chemotherapy-at-home services market going forward. Healthcare expenditure represents the total financial resources allocated by individuals, organizations, and governments toward the prevention, treatment, and management of health conditions. Healthcare spending continues to increase due to advancements in medical technologies, as innovative diagnostic tools, therapies, and treatment approaches often involve higher costs. Rising healthcare expenditure supports the expansion of chemotherapy-at-home services by enabling investment in cost-effective, patient-centered cancer care models, expanding reimbursement frameworks, and strengthening the infrastructure required to deliver safe oncology treatments in home settings. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid programs, U.S. healthcare spending rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per capita. Therefore, the growth in healthcare expenditure is contributing to the expansion of the chemotherapy-at-home services market.

Major companies operating in the chemotherapy-at-home services market are increasingly emphasizing the expansion of patient-centric care models through technology-enabled, home-based oncology programs to improve treatment accessibility, enhance patient comfort, and reduce pressure on hospital systems. These programs combine remote patient monitoring, virtual oncology support, and in-home nursing services to deliver safe and compliant chemotherapy outside conventional clinical environments. For instance, in April 2025, Reimagine Care, a US-based provider of technology-driven home oncology solutions, launched an at-home cancer care pilot in partnership with MedStar Health. This initiative is designed to extend oncology services - such as symptom management, treatment support, and continuous virtual monitoring - into patients’ homes. By utilizing digital platforms, care navigation tools, and specialized clinical teams, the pilot aims to improve patient experience, reduce hospital utilization, and enable more efficient oncology care delivery across the MedStar Health network.

Major companies operating in the chemotherapy at home services market are CVS Health Corporation, Optum Inc, Fresenius Kabi, Medtronic plc, Amgen, Penn Medicine, Advocate Health Care, Medibank Private Limited, Option Care Health Inc., Amedisys Inc., Lincare Holdings Inc., Cancer Treatment Centers of America (CTCA), BioScrip Inc., Shanghai MicroPort Lifesciences Co. Ltd., Accredo Health Group Inc., LloydsPharmacy Clinical Homecare, InfuSystem Holdings Inc., Portea Medical, Amerita Inc., Jivika Healthcare, Vitalis Health and Home Care Pty Ltd, Ubiqare Health Pvt. Ltd., View Health Pty Ltd group, Sciensus Pharma Services Limited, TCP Homecare.

North America was the largest region in the chemotherapy at-home services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy at home services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy at home services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chemotherapy at home services market by increasing costs of imported infusion pumps, oncology drugs, medical consumables, and digital monitoring devices. Healthcare providers in North America and Europe are most affected due to reliance on imported infusion technologies and specialty drugs, while Asia-Pacific faces higher costs in sourcing advanced homecare equipment. These tariffs are increasing service delivery costs and affecting affordability. However, they are also driving domestic manufacturing of infusion devices, localized pharmaceutical production, and expansion of regional home healthcare infrastructure.

The chemotherapy at home services market research report is one of a series of new reports that provides chemotherapy at home services market statistics, including chemotherapy at home services industry global market size, regional shares, competitors with a chemotherapy at home services market share, detailed chemotherapy at home services market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy at home services industry. This chemotherapy at home services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemotherapy at-home services are an outpatient care option delivered by a team of physicians and nurses, enabling cancer patients to receive treatment in their own homes. These services allow patients to undergo chemotherapy in a comfortable home environment rather than in conventional clinical settings such as hospitals or specialized treatment centers.

The products used in chemotherapy at-home services include chemotherapy drugs and chemotherapy infusion pumps. Chemotherapy drugs are medications designed to treat cancer by targeting and destroying cancer cells. These treatments are administered through routes such as oral and intravenous and are used for applications including breast cancer, blood cancer, ovarian cancer, colorectal cancer, and others.

The chemotherapy-at-home services market consists of revenues earned by entities by providing services such as telehealth support, and drug delivery services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-at-home services market also includes sales of portable infusion pumps, chemotherapy drug kits, and home care medical supplies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.